IN2012DN03391A - - Google Patents

Download PDF

Info

Publication number
IN2012DN03391A
IN2012DN03391A IN3391DEN2012A IN2012DN03391A IN 2012DN03391 A IN2012DN03391 A IN 2012DN03391A IN 3391DEN2012 A IN3391DEN2012 A IN 3391DEN2012A IN 2012DN03391 A IN2012DN03391 A IN 2012DN03391A
Authority
IN
India
Prior art keywords
compound
methyl
processes
relates
luoro
Prior art date
Application number
Inventor
David Cantin Louis
Luo Xuehong
Jerzy Tomaszewski Miroslaw
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IN2012DN03391A publication Critical patent/IN2012DN03391A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

This invention generally relates to substituted benzoimidazole compounds, particularly methyl 2-((2-(2,6-di£luoro-4-(methylcarbamoyl)phenyl)-5-methyl-lH-benzo[d]imidazol-l-yl)methyl)morpholine-4-carboxylate and salts thereof. This invention also relates to pharmaceutical compositions and kits comprising such a compound, uses of such a compound (including, for example, treatment methods and medicament preparations), processes for making such a compound, and intermediates used in such processes.
IN3391DEN2012 2009-11-18 2010-11-17 IN2012DN03391A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26226309P 2009-11-18 2009-11-18
PCT/SE2010/051269 WO2011062550A1 (en) 2009-11-18 2010-11-17 Benzoimidazole compounds and uses thereof

Publications (1)

Publication Number Publication Date
IN2012DN03391A true IN2012DN03391A (en) 2015-10-23

Family

ID=44059844

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3391DEN2012 IN2012DN03391A (en) 2009-11-18 2010-11-17

Country Status (16)

Country Link
US (1) US8530467B2 (en)
EP (1) EP2501697B1 (en)
JP (1) JP5657018B2 (en)
KR (1) KR20120113709A (en)
CN (1) CN102741245B (en)
AR (1) AR079050A1 (en)
AU (1) AU2010322478B2 (en)
BR (1) BR112012011518B8 (en)
CA (1) CA2777746C (en)
ES (1) ES2442797T3 (en)
IN (1) IN2012DN03391A (en)
MX (1) MX2012005329A (en)
RU (1) RU2542582C2 (en)
TW (1) TW201121957A (en)
UY (1) UY33037A (en)
WO (1) WO2011062550A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012158117A1 (en) * 2011-05-17 2012-11-22 Astrazeneca Ab Combination therapies for treating pain
PT3381917T (en) * 2013-01-31 2021-10-27 Bellus Health Cough Inc Imidazopyridine compounds and uses thereof
CN105992761A (en) * 2013-12-20 2016-10-05 盐野义制药株式会社 Methods respectively for producing optically active compound having agonistic activity on thrombopoietin receptors and intermediate of said compound
WO2016004358A1 (en) 2014-07-03 2016-01-07 Afferent Pharmaceuticals, Inc. Methods and compositions for treating diseases and conditions
US10111883B1 (en) * 2017-09-18 2018-10-30 Bellus Health Cough Inc. Selective P2X3 modulators
CN108904507A (en) * 2018-02-11 2018-11-30 赖英杰 P2X3 receptor modulators benzimidazole compound is preparing the application in anti-respiratory disorder drug
US20240034729A9 (en) * 2018-12-29 2024-02-01 Wuhan Ll Science And Technology Development Co., Ltd. Heterocyclic compound, intermediate, preparation method therefor and application thereof
KR20230051209A (en) * 2020-08-13 2023-04-17 투오지에 바이오텍 (상하이) 컴퍼니 리미티드 Benzimidazole derivatives, their preparation methods and their medical uses
TW202227458A (en) * 2020-12-04 2022-07-16 大陸商上海拓界生物醫藥科技有限公司 Compounds containing fused tricyclic rings and medical use thereof
CN114478508A (en) * 2021-12-31 2022-05-13 淮北师范大学 Crystalline form of a benzimidazole compound
TW202337452A (en) * 2022-02-11 2023-10-01 大陸商江蘇恒瑞醫藥股份有限公司 A pharmaceutical salt of p2x3 receptor antagonist and preparation method thereof
WO2023151660A1 (en) * 2022-02-11 2023-08-17 江苏恒瑞医药股份有限公司 Crystalline form of p2x3 receptor antagonist, and preparation method therefor

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6026A (en) * 1849-01-09 Cast-iron car-wheel
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
SK285141B6 (en) 1996-02-13 2006-07-07 Astrazeneca Uk Limited Use of quinazoline derivative, quinazoline derivative, process for preparation thereof and pharmaceutical composition containing thereof
EP0885198B1 (en) 1996-03-05 2001-12-19 AstraZeneca AB 4-anilinoquinazoline derivatives
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
EE05345B1 (en) 1999-02-10 2010-10-15 Astrazeneca Ab Quinazoline derivatives as inhibitors of angiogenesis
CZ301504B6 (en) * 2000-01-17 2010-03-24 Teijin Limited Benzimidazole derivatives
MXPA02011770A (en) 2000-05-31 2003-04-10 Astrazeneca Ab Indole derivatives with vascular damaging activity.
UA73993C2 (en) 2000-06-06 2005-10-17 Астразенека Аб Quinazoline derivatives for the treatment of tumours and a pharmaceutical composition
IL153484A0 (en) 2000-07-07 2003-07-06 Angiogene Pharm Ltd Colchinol derivatives as angiogenesis inhibitors
WO2002008213A1 (en) 2000-07-07 2002-01-31 Angiogene Pharmaceuticals Limited Colchinol derivatives as angiogenesis inhibitors
RU2374234C2 (en) * 2004-09-24 2009-11-27 Астразенека Аб Benzimidazole derivatives, compositions containing said derivatives, production and use thereof
BRPI0808707A2 (en) * 2007-03-02 2014-09-09 Schering Corp USE OF BENZIMIDAZOLE DERIVATIVES AND COMPOSITION UNDERSTANDING THE SAME
US20090099195A1 (en) 2007-05-08 2009-04-16 Astrazeneca Ab Therapeutic Compounds 570
WO2009058298A1 (en) * 2007-10-31 2009-05-07 Merck & Co., Inc. P2x3, receptor antagonists for treatment of pain

Also Published As

Publication number Publication date
EP2501697A1 (en) 2012-09-26
CA2777746A1 (en) 2011-05-26
US20120289504A1 (en) 2012-11-15
BR112012011518B8 (en) 2023-01-10
RU2012124268A (en) 2013-12-27
AU2010322478B2 (en) 2013-11-14
EP2501697A4 (en) 2013-04-24
BR112012011518A2 (en) 2016-06-28
CN102741245B (en) 2014-11-05
UY33037A (en) 2011-06-30
CN102741245A (en) 2012-10-17
CA2777746C (en) 2019-05-14
MX2012005329A (en) 2012-05-29
WO2011062550A1 (en) 2011-05-26
AR079050A1 (en) 2011-12-21
ES2442797T3 (en) 2014-02-13
JP5657018B2 (en) 2015-01-21
KR20120113709A (en) 2012-10-15
JP2013511517A (en) 2013-04-04
TW201121957A (en) 2011-07-01
US8530467B2 (en) 2013-09-10
EP2501697B1 (en) 2013-10-23
AU2010322478A1 (en) 2012-05-31
BR112012011518B1 (en) 2020-03-10
RU2542582C2 (en) 2015-02-20

Similar Documents

Publication Publication Date Title
IN2012DN03391A (en)
MX339193B (en) 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]mor pholine hydrochloride polymorphs and solvates.
MY183588A (en) New salvianolic acid compound l, preparation method and use thereof
GEP20166432B (en) 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
UA102179C2 (en) Fungicidal composition
UA95644C2 (en) Pyridizinone derivative, pharmaceutical composition and treatment method
UA106199C2 (en) Aminobenzamide derivatives as agents suitable for controlling animal parasites
JO2962B1 (en) Substituted aminopropionic derivatives as neprilysin inhibitors
CL2011002840A1 (en) Compound derived from pyrazole carboxamide; fungicidal composition comprising said compound; process for preparing said compound; intermediate compounds; and use of said compound to control phytopathogenic fungi and reduce mycotoxins.
UA101819C2 (en) Herbicidal 1h-2-thia-1,5,8-triazanaphthalene-2,2-dioxides
MX2012007935A (en) Fungicidal heterocyclic compounds.
BR112012009214A2 (en) compounds
NZ593874A (en) Nalmefene hydrochloride dihydrate
IN2012DN01298A (en)
MY151229A (en) Crystalline form of a 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compound
UA112055C2 (en) SALTS 4- [2 - [[5-METHYL-1- (2-NAPHTHALINYL) -1H-PYRAZOL-3-yl] OXY] ETHYL] MORPHOLINE
UA96759C2 (en) 2-ARYLINDOLE DERIVATIVES AS mPGES-I INHIBITORS
ME00961B (en) Derivatives of 7-alkynyl-1,8-naphthyridones, preparation method thereof and use of same in therapeutics
BR112012012755A2 (en) "Compound of formula (i), fungicidal composition and method for control of crop phytopathogenic fungus"
UA107831C2 (en) Composition for combating plant diseases and its application
WO2009145591A3 (en) Phenyl piperazine compounds, pharmaceutical composition including the same, and use thereof
WO2010056644A8 (en) 1-(arylsulfonyl)-4-(piperazin-1-yl)-1h-benzimidazoles as 5-hydroxytryptamine-6 ligands
MY173914A (en) Pesticidal composition and method for controlling pests
UA105022C2 (en) Composition for controlling plant diseases and a method for controlling plant diseases
UA110577C2 (en) Agent for controlling plant diseases, a method for controlling plant diseases and a product for controlling diseases